Dr. Omnia Ayman is the Manager of the Biological Protocols Unit and GCP Inspector at the Egyptian Drug Authority (EDA). She specializes in clinical research regulation and in the evaluation of preclinical studies and clinical trials involving biologicals, biosimilars, and vaccines. She also conducts Good Clinical Practice (GCP) inspections at clinical trial sites and relevant entities to verify adherence to GCP principles.

Dr. Omnia participated in the evaluation of COVID-19 vaccines during the pandemic period, supporting national efforts to ensure their safety, efficacy, and regulatory compliance. She has also served as a focal point for the World Health Organization (WHO) benchmarking of regulatory systems, contributing to Egypt achieving Maturity Level 3 in the vaccine regulatory field.